Evommune, Inc.

NYSE:EVMN

Biotechnology

Healthcare
$6.88 -0.82%

-$0.17 today

Market cap
$284.49M
Beta
0.10
P/E (TTM)
-9.1
EPS (TTM)
-$2.26
52W Low $13.89High $33.20

Volume 0.60M

Average 0.38M

EVMN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Evommune, Inc.NYSE: EVMN

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow grows to $0

Q1 FY2026 stock-based compensation was $0, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $0.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 0 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Stock-Based Compensation vs competitors

How EVMN compares with its peers on the latest reported figures

  • EVMN's LTM Mar 2026 stock-based compensation of $0 is the smallest of the 10 companies compared; the peer median is $15.02M.
  • Stock-based compensation amounts to 0.0% of revenue for EVMN, versus a peer median of 14.3%.
EVMN Competitors Peer median
Stock-Based Compensation for EVMN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FTREFortrea Holdings Inc.LTM Jun 2026$61.1M +21.5%+43.1%2.3%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$53.27M +57.8%—18.3%
ZYMEZymeworks Inc.LTM Sep 2026$37.94M +56.7%+91.1%14.3%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$31.69M -0.5%+25.3%416.2%
OABIOmniAb, Inc.LTM Mar 2026$15.02M -24.7%-4.8%52.0%
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$13.5M -20.7%-26.5%8.9%
CDXSCodexis, Inc.LTM Mar 2026$8.67M -29.5%-12.8%11.1%
CLYMClimb Bio, Inc.LTM Mar 2026$7.64M +7.4%+4.8%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$6.36M -16.6%+1.2%—
EVMNEvommune, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding EVMN) $15.02M-0.5%+3.0%14.3%

Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.05M)(66.81M)(68.87M)
Depreciation & Amortization1M1.29M1.39M
Deferred Income Tax000
Stock-Based Compensation000
Change in Working Capital3.34M7.42M(4.12M)
Accounts Receivables000
Inventory000
Accounts Payables125K6.51M(837K)
Other Working Capital3.22M918K(3.28M)
Other Non-Cash Items(261K)(98K)(4.84M)
Operating Cash Flow(29.97M)(58.2M)(76.44M)
Capital Expenditures(118K)(88K)(235K)
Acquisitions (Net)000
Purchases of Investments(91.31M)(90.26M)(199.17M)
Sales of Investments43M86.35M84.1M
Other Investing Activities000
Investing Cash Flow(48.43M)(3.99M)(115.31M)
Debt Repayment00(373K)
Common Stock Issued63.98M49.84M222.36M
Common Stock Repurchased000
Dividends Paid000
Other Financing Activities(230K)(423K)(1.22M)
Financing Cash Flow63.75M49.42M220.76M
Effect of Forex Changes43.67M(1)(1.21M)
Net Change in Cash29.02M(12.77M)27.81M
Free Cash Flow(30.09M)(58.28M)(76.68M)

Evommune, Inc.

NYSE:EVMN

Intrinsic Alpha fair value

Locked

Current Price

$6.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.